Hepatitis
C Top News Articles |
|
 FDA
Advisory Panel Urges "Black Box" Warning -- and Potential Ban -- on
Prescription Acetaminophen Combinations Due
to Liver Toxicity
7-03-2009 |
 Albumin
Interferon (Albuferon) and HCV Polymerase Inhibitor PSI-7851
Advance in Clinical Trials
7-03-2009 |
 CDC
Researchers Release Latest Hepatitis A, B, and C Statistics
6-23-2009 |
 Detectable
HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients
Treated with Pegylated Interferon plus Ribavirin
6-23-2009 |
Effectiveness
of Pegylated Interferon plus Ribavirin for
Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009 |
 Blood
Pressure Drug Losartan Associated with Liver Fibrosis Regression in
Small Study
6-19-2009 |
FDA
Alert Warns of Elevated Risk of Death in Liver Transplant Recipients Who Switch
to Rapamune (Sirolimus)
6-16-2009 |
 Many
People with Chronic Hepatitis B and C Do Not Receive
Appropriate Treatment
6-16-2009 |
Older
Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based
Therapy
6-16-2009 |
Metabolic
Syndrome Is Associated with Increased Risk of Hepatocellular
Carcinoma in Chronic Hepatitis C Patients
6-9-2009 |
Strategies
for Managing Acetaminophen-related Liver Disease
and Acute Liver Failure
6-5-2009 |
Vitamin
B12 Levels May Help Predict Response to Interferon-based
Therapy for Chronic Hepatitis C
6-5-2009
|
HCV
Viral Load Decline at Day 2 of Interferon-based Therapy
Predicts Sustained Response, Explains Poorer Outcomes in African-Americans
6-2-2009 |
Virco
and Siemens Diagnostics Sign Licensing Agreement Allowing Virco to Develop New
Platform for Use in Development of New Therapies for
Hepatitis C
6-2-2009 |
|
 Report
Predicts Costly Epidemic of Advanced Liver Disease
among Baby Boomers with Chronic Hepatitis C
5-29-2009 |
 Reduced
Dose and Duration of PegIntron plus Ribavirin
Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients
5-29-2009 |
IDEAL
Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated
Interferon plus Ribavirin Is Associated with Better Response
5/22/09 |
 On
World Hepatitis Day, Ask "Am I Number
12?"
5/22/09 |
On
World Hepatitis Day, Ask "Am I Number 12?"
5/19/09 |
Active
Injection Drug Users and Those on Opiate
Substitution Treatment Can Have Good Hepatitis C Therapy Outcomes
5/19/09 |
Researchers
Report Promising Results from Studies of 3 Therapeutic
HCV Vaccines
5/19/09 |
FDA
Approves Dose Adjustments of PegIntron and Rebetol for
Certain Patients with Chronic Hepatitis C
5/15/09 |
Hepatitis
C Treatment Is More Successful before Progression to Advanced Liver
Damage
5/15/09 |
Chronic
Hepatitis C Patients with Metabolic Syndrome
Are at Greater Risk of Death
5/08/09 |
Extended
72-week Treatment with Pegylated Interferon plus Ribavirin
Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09 |
Early
Treatment of Acute Hepatitis C with Pegylated
Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
5/05/09 |
Pegylated
Interferon alfa-2b (PegIntron) Maintenance Monotherapy May Reduce Esophageal
Varices in Hepatitis C Patients with Cirrhosis
5/05/09 |
Adding
Telaprevir Improves Sustained Response to
Pegylated Interferon plus Ribavirin in Genotype
1 Chronic Hepatitis C Patients (PROVE3)
5/01/09 |
Experimental
HCV Protease Inhibitor SCH 900518, with or
without Pegylated Interferon, Appears Safe
and Exhibits Good Antiviral Activity
5/01/09 |
 FDA
Will Require Additional Warning Labels for Over-the-Counter
Painkillers, Including Tylenol, Aspirin and Ibuprofen
5/01/09 |
Promising
Early Results from the First Clinical Trial of a Combination Regimen of 2
Oral Antiviral Agents for Chronic Hepatitis C
4/28/09 |
Adding
Boceprevir to PegIntron/Ribavirin Significantly
Improves Sustained Virological Response in Chronic Hepatitis C Patients
4/28/09 |
 Genes
that Regulate Interferon Signaling May Help
Explain Reduced Response to Hepatitis C Therapy in African-American Patients
4/28/09 |
Re-treatment
of Chronic Hepatitis C Patients Who Do Not Respond to Pegylated
Interferon Alfa-2b (PegIntron)
4/24/09 |
Liver
Cancer Drug Sorafenib (Nexavar) May Also Alleviate
Complications Due to Cirrhosis
4/24/09 |
Interferon-based
Therapy for Hepatitis C Improves
Fibrosis Even in Individuals without Virological Response
4/21/09 |
 Sustained
Response to Interferon-based Therapy Reduces
Risk of Diabetes in Hepatitis C Patients
4/21/09
|
 HCV
Vaccine Development
4/13/09 |
A
Small Proportion of Hepatitis C Patients Develop Liver
Cancer despite Sustained Response to Interferon-based
Therapy
4/13/09 |
Treatment
for HCV/HBV Coinfection
4/10/09 |
Pharmasset
Initiates First Clinical Trial of Second-generation HCV Polymerase
Inhibitor PSI-7851
4/10/09 |
Pegylated
Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis
C Patients Depend on Weight-based Ribavirin Dosage
4/07/09 |
Overview
of the Current Standard of Care for Treatment of Chronic
Hepatitis C
4/03/09 |
HCV
Reinfection and Superinfection Are Common among Injection Drug Users
3/24/09 |
Review
Finds Albumin Interferon for Chronic Hepatitis
C Is Effective and Well-tolerated; Phase 3 Results Show Non-inferiority to Pegylated
Interferon
3/20/2009
|
Long-term
Maintenance Interferon Did Not Prevent Hepatocellular Carcinoma among Chronic
Hepatitis C Patients in HALT-C Study
3/17/2009 |
FDA
Approves New Indication for PegIntron plus Ribavirin
for Certain Patients Who Failed Prior Hepatitis C Treatment
3/13/2009 |
U.S.
Liver Cancer Rate Triples, but Survival Improves
3/13/2009 |
Vertex
Acquires VCH-222 and VCH-759, Two Experimental
Oral HCV Polymerase Inhibitors
3/09/2009
|
 Merck
Will Buy Schering-Plough for $41.1 Billion
3/09/2009 |
 Open
Phase 3 Study of Eltrombopag for Raising Platelet
Levels in Patients with Chronic Liver Disease and Thrombocytopenia
2/27/09 |
 Phase
1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated
Interferon plus Ribavirin
2/27/09 |
Abbott
and Enanta Announce First Clinical Trial of Oral HCV Protease
Inhibitor ABT-450
2/20/2009
|
iTherX
Pharmaceuticals Announces Phase 2a Proof-of-concept Trial of First Hepatitis
C Virus Entry Inhibitor
2/13/2009
|
Cyclical
Treatment Interruption in Patients Taking Interferon-based
Therapy for Chronic Hepatitis C
2/10/2009
|
 Hepatitis
C Virus May Persists at Low Levels after Sustained Response to Treatment; Liver
Cancer May Develop Years Later
2/06/2009
|
Extended
Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in
Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009
|
Debiopharm
Begins Randomization of Participants in Phase 2b Trial of Cyclophilin Inhibitor
Debio 025 for Chronic Hepatitis C
2/03/2009
|
Adherence
to Pegylated Interferon/ribavirin Therapy
for Hepatitis C and Early Treatment Response
1/30/2009
|
Schering-Plough
Completes Enrollment of Phase 3 Trial of HCV Protease Inhibitor Boceprevir
1/30/2009
|
Combination of Virus and Host Factors Predict Virological
Response to Pegylated Interferon plus Ribavirin
for Chronic Hepatitis C
1/27/2009
|
 Elevated Risk of Biliary and
Pancreas Cancer in Chronic Hepatitis C Patients
1/27/2009
|
 Companies
Announce Phase 1b Study Data for Experimental HCV Polymerase Inhibitor ANA598
and Cyclophilin Inhibitor SCY635
1/23/2009
|
 Liver
Biopsies Indicate Persistent Inflammation and Fibrosis
in HCV Antibody Positive People with Undetectable HCV RNA
1/23/2009
|
Early Discontinuation of Ribavirin
May Be Appropriate for Selected Genotype 2 or 3 Chronic Hepatitis C Patients
1/20/2009
|
New Hepatitis C Treatment
Trials: HCV Polymerase Inhibitor R7128, Nucleotide Prodrug IDX184,
and Albumin Interferon (Albuferon)
1/20/2009
|
Vital Therapies Starts Phase 2 Trial of Artificial
Liver Support System
1/20/2009
|
Latino
Hepatitis C Patients Have a Lower Rate of Sustained Response to Pegylated
interferon plus Ribavirin than Whites
1/16/2009
|
InterMune
Reports Results from Triple Combination Study of HCV
Protease Inhibitor ITMN-191
1/16/2009 |
Adefovir
plus Hepatitis C Therapy May Prevent HBV Reactivation in HBV-HCV Coinfected
Patients
1/16/2009 |
MELD
Eliminated Racial Disparities in Liver Transplantation,
but Women Are Still at a Disadvantage
1/16/2009 |
 Effects
of Alcohol on HCV Replication and Treatment
Response
1/13/2009 |
 Study
Shows Treating Prisoners with Hepatitis C
Is Cost Effective
1/13/2009 |
| Albumin
Interferon (Albuferon) Works as Well as Pegylated Interferon in ACHIEVE
2/3 Trial - 1/13/2009 |
| Naturally
Occurring Resistance to HCV Protease and Polymerase Inhibitors
in Treatment-naive Hepatitis C Patients -
1/09/2009 |
PegIntron
plus Ribavirin Approved for Children with Chronic Hepatitis C -
1/05/2009 |
New
Genetic Test May Help Predict Response to Hepatitis C Treatment
-
1/05/2009 |
 Liver
Disease Progression and Treatment Response in Latino and Asian Patients
with Chronic Hepatitis C -
12/12/2008 |
| Silibinin
Milk Thistle Extract Demonstrates Antiviral Activity in Non-responders
to Interferon-based Therapy for Chronic Hepatitis C -
12/12/2008 |
| SAMe
Improves Early Response to Pegylated Interferon/ribavirin
in Small Study -
12/12/2008 |
 Is
Maintenance Therapy with Pegylated Interferon Monotherapy
Ineffective-or Even Harmful to Patients? -
12/12/2008 |
 Long-term
Low-dose Pegylated Interferon May Improve
Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders
-
12/08/2008 |
| Results
of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis
C: A Slide Set Review -
12/082008 |
 CD4
T-cell Responses to HCV during and after Interferon-based
Therapy for Chronic Hepatitis C -
12/05/2008 |
| Nitazoxanide
Enhances Anti-HCV Activity of Pegylated interferon/ribavirin
and STAT-C Agents -
12/02/2008 |
| Prodrug
Taribavirin Produces Equivalent Response, but Less Anemia than Ribavirin
at 48 Weeks -
12/02/2008 |
| Extended
Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
-
11/25/2008 |
| Three
New STAT-C Agents Show Promise in Preclinical Studies and Early Clinical Trials:
MK-7009, ANA598, and IDX375 -
11/25/2008 |
| Therapies
to Manage Insulin Resistance Improve Response to Interferon-based
Therapy in Chronic Hepatitis C Patients -
11/21/2008 |
| Canadian
POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated
Interferon plus Ribavirin -
11/21/2008 |
| Genotype
1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of
Pegylated Interferon plus Ribavirin
-
11/18/2008 |
| Sexual
Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based
Therapy for Chronic Hepatitis C -
11/14/2008 |
| HCV
Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in
Genotype 2 or 3 Prior Non-responders and Relapsers -
11/14/2008 |
| HCV
Protease Inhibitor ITMN-191 (R7227) Demonstrates Antiviral Potency
in Genotype 1 Patients; New ITMN-5489 Also Under Study -
11/14/2008 |
| R7128
plus ITMN-191 Perform Well in Laboratory Study; STAT-C Combination
Clinical Trial Now Underway -
11/14/2008 |
| HCV
Protease Inhibitor Telaprevir (VX-950) Continues
to Perform Well in PROVE Trials -
11/11/2008 |
| Experimental
HCV Protease Inhibitor TMC435350 Demonstrates
Favorable Safety and Efficacy in Phase 2a Trial -
11/11/2008 |
| Investigational
HCV Protease Inhibitor BI 201335 Exhibits
Promising Antiviral Activity -
11/11/2008 |
| HCV
Polymerase Inhibitor PF-00868554 Inhibits
Viral Replication in Treatment-naive Patients -
11/11/2008 |
| IDEAL
Researchers Look at Predictors of Response to Pegylated
Interferon plus Ribavirin, including Race/ethnicity and Anemia
-
11/07/2008 |
| Several
“STAT-C” Agents Discussed at the Liver Meeting
-
11/07/2008 |
| HCV
Protease Inhibitor Boceprevir plus Pegylated Interferon/Ribavirin
Increases Sustained Virological Response Rate: SPRINT-1 Study -
11/04/2008 |
 Many
U.S. Veterans -- both HIV Negative and HIV Positive -- Do Not Receive Treatment
for Chronic Hepatitis C -
11/04/2008 |
 Hepatitis
C Virus Infection Is Associated with Elevated Cardiovascular Risk despite
Lower Blood Lipid Levels - 10/28/2008 |
 (13)C-methacetin
Breath Test for Non-invasive Assessment of Liver Fibrosis in Chronic
Hepatitis C Patients - 10/24/2008 |
 Tibotec
Begins Enrolling Phase III Study of HCV Protease Inhibitor
Telaprevir for Hepatitis C Patients with Prior Treatment Failure
- 10/24/2008 |
| Response
to Pegylated Interferon plus Ribavirin in
Asian Patients with Genotype 1 Chronic Hepatitis C -
10/21/2008 |
| Genelabs
Announces Data on 3 New HCV Polymerase Inhibitors
- 10/21/2008 |
 Hepatitis
C Virus Coinfection May Suppress Hepatitis B Virus Replicatio -
10/17/08 |
| Pegylated
Interferon plus Ribavirin Produces High Sustained Response Rate in
HBV-HCV Coinfected Individuals - 10/17/08 |
| Sustained
Virological Response Indicates Long-term HCV Eradication in People
Successfully Treated for Chronic Hepatitis C -
10/14/08 |
| 24
Weeks of Pegylated Interferon plus Ribavirin
May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with
Rapid Response -
10/14/08 |
| Individuals
with HCV Genotype 6 Respond Well to Pegylated Interferon
plus Ribavirin -
10/14/08 |
| Higher
Doses of Pegylated Interferon and Ribavirin
May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis
C -
10/10/08 |
| Sustained
Virological Response to Pegylated Interferon plus Ribavirin
for Chronic Hepatitis C Does Not Always Prevent Hepatocellular
Carcinoma -
10/10/08 |
 Hepatitis
C Treatment in Prisons Is Feasible and Produces Good Outcome -
10/07/08 |
| SciClone
Experimental Immunomodulator SCV-07 Shows
Promise as Monotherapy in Prior Relapsers to Standard Treatment for Chronic Hepatitis
C -
10/03/08 |
| Natural
Prevalence of Resistance to HCV Protease Inhibitors
- 9/25/08 |
| Albumin
Interferon (Albuferon) Administered Once Every 2-4 Weeks May Be As
Effective as Once-weekly Pegylated Interferon -
9/23/08 |
 Kidney
Disease in Patients with Chronic Hepatitis C
- 9/23/08 |
 Further
Evidence Shows that Hepatitis C Virus (HCV) Can Be Transmitted
through Snorting Drugs - 9/19/08 |
 HCV
May Be Transmitted via Blood-contaminated Surfaces
- 9/19/08 |
 Is
HCV Transmitted within Families in Endemic Countries?
- 9/19/08 |
|
Liver
Fibrosis Progression Rates in HCV Monoinfected and HIV-HCV Coinfected
Individuals -
9/16/08 |
|
Impact of Diet on Fibrosis
Progression and Response to Treatment in People with Chronic
Hepatitis C -
9/16/08 |
Successful Treatment Is Reducing
Mortality Due to Hepatitis C in France -
9/12/2008 |
 Combination
Therapy with Investigational HCV Polymerase Inhibitor
R7128 Produces Rapid Response in Patients with Genotype 2/3 HCV
-
9/12/2008 |
STORM
Trial to Assess Sorafenib (Nexavar) as Adjuvant Therapy for Patients
with Liver Cancer -
9/12/2008 |
 Genetic
Variation Linked to Sustained Response to Pegylated Interferon
plus Ribavirin in HALT-C Trial -
9/09/2008 |
| Older
Donor Liver Grafts May Be Suitable for Chronic Hepatitis
C Patients Requiring Transplantation -
9/05/08 |
| Insulin-sensitizing
Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment
with Pegylated Interferon plus Ribavirin -
8/29/2008 |
| Rosiglitazone
(Avandia) Improves Liver Enzyme Levels and Steatosis -- but not Fibrosis
-- in Patients with Non-alcoholic Fatty Liver Disease -
8/29/2008 |
 Are
HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment
with Pegylated Interferon plus Ribavirin
- 8/19/2008 |
 Body
Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated
with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin
- 8/12/2008 |
| Pharmasset
Releases Preliminary Data from Phase 1 Study of Investigational HCV
Polymerase Inhibitor R7128 - 8/08/2008 |
 Rapid
Viral Response and Sustained Treatment Outcome: A Comparison between
2 HCV RNA Assays - 8/05/2008 |
| Eight
Weeks of Pegylated Interferon plus Ribavirin
for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR)
- 8/05/2008 |
 74
Percent of Genotype 1 HCV Patients in Experimental HCV
PI Boceprevir Phase II Study Achieve Sustained Virologic Response (SVR)
at 48 Weeks - 8/05/2008 |
 Detectable
HCV Is Associated with Altered Serum Triglyceride and
Cholesterol Level - 8/01/08 |
 Genetic
Variations May Help Explain Racial/ethnic Differences in Immune Response
to Hepatitis C Virus -
7/29/08 |
 Study
Demonstrates Safety of Erythropoiesis-stimulating Agents for Managing Ribavirin-related
Anemia in Hepatitis C Patients -
7/29/08 |
| Hepatocellular
Carcinoma Rates Vary Widely Across Sex and Racial/Ethnic Groups
-
7/25/08 |
| Two
Studies Look at Promising Therapies for Liver Cancer
-
7/25/08 |
 Telaprevir
plus Pegylated Interferon and Ribavirin Produces Rapid Response and
Is Well Tolerated in 28-day Study -
7/22/08 |
 Active
Injection Drug Use Does Not Impair Sustained Response to Hepatitis
C Treatment in Adherent Patients -
7/22/08 |
 Comparison
of the Pegylated Interferons Pegasys and PegIntron
for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials -
7/18/08 |
| Obesity
and Steatosis Influence Serum and Liver Inflammatory Markers in People
with Chronic Hepatitis C -
7/18/08 |
 Obesity
and Diabetes Are Linked to Increased Risk of Liver Cancer -
7/18/08 |
 Experimental
HCV Polymerase Inhibitor R1626 Demonstrates
Potent Viral Suppression, but Often Causes Neutropenia -
7/15/08 |
 12-
Versus 24-week Treatment with Pegylated Interferon plus
Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients -
7/11/08 |
| Prevalence
of Hepatitis C Virus Infection among Injection Drug Users
in the U.S. -
7/11/08 |
 FDA
Revises Process for Responding to Drug Approval Applications
from Pharmaceutical Companies -
7/11/08 |
 Studies
Explore Lower Doses of Pegylated Interferon and Ribavirin
for People with Hepatitis C Virus Genotypes 2 or 3 -
7/08/08 |
| Adequate
Ribavirin Exposure after the First Dose Predicts Sustained Virological
Response to Hepatitis C Treatment in Genotype 1 Patients -
7/08/08 |
| HCV
Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks
of Treatment, despite Rapid Virological Response -
7/04/08 |
 European
Commission Approves Shorter 16-week Course of Pegasys
plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low
Viral Load -
7/04/08 |
| Insulin
Resistance and Diabetes Increase the Risk of Liver
Fibrosis and Hepatocellular Carcinoma in People with Chronic Hepatitis
C
-
7/04/08 |
| Sustained
Response to Interferon-based Therapy Reduces
the Likelihood of Type 2 Diabetes
- 6/24/08 |
 Aspirin
(Acetylsalicylic Acid) Inhibits HCV Replication
in Laboratory Study - 6/20/08 |
 Course
of Chronic
Hepatitis C in Children -
6/17/08 |
| Study
Review Confirms High Cure Rate for Acute Hepatitis C,
but Treatment Dilemma Persists - 6/17/08 |
| Vertex
Reports Encouraging Data from PROVE3 Trial of HCV Protease Inhibitor
Telaprevir (VX-950) -
6/13/08 |
 Pegylated
Interferon plus Ribavirin for 48 Weeks is Superior to 24 Weeks for
Patients with HCV Genotype 6 - 6/13/08 |
 Association
between Hepatitis B and C Virus Infection
and Extrahepatic Bile Duct Cancer - 6/13/08
|
| Selected
Hepatitis C Patients with Decompensated Cirrhosis
Can Benefit from Interferon-based Therapy
prior to Liver Transplantation -
6/10/08 |
 Herbal
Product Stevioside Inhibits HCV Replication and Curcumin Suppresses
Fibrogenic Cell Activity in Laboratory Studies -
6/10/08 |
| Active
and Recovering Injection Drug Users Can Benefit
from Hepatitis C Treatment if They Maintain Good Adherence -
6/10/08 |
| InterMune
and Anadys Begin Phase 1 Clinical Trials of Experimental HCV Therapies ITMN-191
and ANA598 -
6/06/08 |
 Mortality
Due to Hepatitis C in the U.S.: Has the Worst Passed? -
6/06/08 |
 Marijuana
Use Sparks Liver Transplant Controversy
-
6/06/08 |
 Chronic
Hepatitis C May Contribute to an Elevated Risk of Bone
Fractures in Postmenopausal Women -
6/03/08 |
| Sustained
Virological Response to Pegylated Interferon Alfa-2b
(PegIntron) with or without Ribavirin Predicts Continued Response through
5 Years -
5/30/08 |
| Very
Early Response to Interferon-based Therapy
for Hepatitis C Is Apparent within the First 24 Hours -
5/30/08 |
| Schering
Plough Initiates Phase 3 Studies with Experimental Oral HCV Protease Inhibitor
Boceprevir in Treatment-naive HCV Patients
and in Those Who Failed Prior Treatment -
5/23/08 |
| Significance
of Transient HCV Viral Load "Blips" during Interferon-based
Therapy for Chronic Hepatitis C -
5/23/08 |
| Safety
and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon)
in Genotype 2/3 Chronic Hepatitis C Patients -
5/23/08 |
| Antiviral
Activity, Pharmacodynamics, and Quality of Life in Genotype 1 Hepatitis C Patients
Treated with Albinterferon (Albuferon)
- 5/23/08 |
| Response
to Controlled-release Interferon Alfa-2b (Locteron)
in Genotype 1 Hepatitis C Patients -
5/23/08 |
| Symptoms
and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
- 5/23/08 |
| Response
to Interferon-based Therapy in Hispanic Patients
with Chronic Hepatitis C -
5/20/08 |
| Platelet
Count Is a Strong Predictor of Sustained Response to Pegylated
Interferon/ribavirin in Prior Non-Responders (EPIC 3) -
5/20/08 |
| Amino
Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated
Interferon/ribavirin in Genotype 1b Patients -
5/20/08 |
| HCV
May Inhibit HBV Replication in HCV-HBV Coinfected Patients -
5/20/08 |
| FibroScan
Liver Stiffness Measurement Distinguishes Fast and Slow Fibrosis Patterns after
Liver Transplantation -
5/16/08 |
| Incidence
of and Risk Factors for Hepatocellular Carcinoma
in Hepatitis C Patients with Advanced Liver Disease: HALT-C Trial -
5/16/08 |
|
FDA-approved
Combination Therapies for Chronic HCV Infection
